Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2009 Apr 1;15(7):2205-6.
doi: 10.1158/1078-0432.CCR-08-2905. Epub 2009 Mar 17.

Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?

Richard F Ambinder  1
Affiliations
Comment

Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis?

Richard F Ambinder. Clin Cancer Res. .

Abstract

Splizimomab, an antibody that targets CD2, was studied in the treatment of T and natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.

PubMed Disclaimer

Conflict of interest statement

Disclosure of Potential Conflicts of Interest: No potential conflicts of interest were disclosed.

Figures

Fig. 1
Fig. 1
A, rare resting memory B cells harbor viral genomes (gray nuclei) but do not express viral genes that lead to B cell proliferation or antigenicity. Lytic activation of a latently infected B cell leads to the death of that cell and the release of virions (orange) that infect other B cells. Newly infected B cells (orange) express latency proteins, including immunodominant antigens, which drive proliferation. T cells kill proliferating EBV-infected B cells. Equilibrium is maintained. B, with diminished numbers of T cells, EBV-infected B cells are more likely to proliferate. C, with diminished numbers of B and T cells, there is no EBV B cell proliferation.
See this image and copyright information in PMC

Comment on

References

    1. O'Mahony D, Morris J, Stetler-Stevenson M. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. Clin Cancer Res. 2009;15:2514–22. - PMC - PubMed
    1. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med. 1990;323:1723–8. PubMed. - PubMed
    1. Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekker AW, Verdonck LF. Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique. Bone Marrow Transplant. 2002;29:335–9. doi: 10.1038/sj.bmt.1703362. PubMed. - DOI - PubMed
    1. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16. PubMed. - PubMed
    1. Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH. X-Linked agamma globulinemla patients are not infected with Epstein-Barr virus: implications for the biology of the virus. J Virol. 1999;73:1555–64. PubMed. - PMC - PubMed

MeSH terms